drugset

drugset / Trial / NCT07511127

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

NCT07511127 ↗

Phase 3 Recruiting 218 enrolled Ruijin Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.

Timeline

Start: 2026-02-28
Primary completion: 2027-12-31
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Maribavir	Small molecule	400 mg	Oral

Indications